<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2913">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02891343</url>
  </required_header>
  <id_info>
    <org_study_id>2013_44</org_study_id>
    <secondary_id>2014-A00513-44</secondary_id>
    <nct_id>NCT02891343</nct_id>
  </id_info>
  <brief_title>Effect of Hypoxia on Cognitive Assessment and Cerebral Activity in Healthy Volunteers</brief_title>
  <acronym>Hypoxia</acronym>
  <official_title>Effect of Hypoxia on Cognitive Assessment and Cerebral Activity in Healthy Volunteers WP1 P002 PHARMACOG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The early assessment of new symptomatic drugs for Alzheimer disease remains difficult because&#xD;
      of the lack of predictive end-point. The use of a battery including different parameters&#xD;
      could improve this early development. In healthy volunteers, to test the reverse effect of&#xD;
      symptomatic drugs, it is necessary to induce transient and reversible cognitive impairment&#xD;
      and cerebral activity changes by a challenge test. In this context, a transient hypoxia could&#xD;
      be relevant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the mean of response latency to the Rapid Visual Information Processing (RVIP) test of the CANTAB battery</measure>
    <time_frame>Between baseline (normoxic period) and Day 0 (hypoxia session )</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of adverse events occuring during the period of hypoxia</measure>
    <time_frame>at the baseline and after the hypoxia session (day0)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Alteration of Cognitive Function</condition>
  <condition>Hypoxia</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2-hour period of hypoxia</intervention_name>
    <description>During this period, the FiO2 will be set on 21% (normoxia condition). A filter will be put between the mask and the tubes connecting it to the machine generating hypoxia (equipment reference = Altitrainer NP190). On that filter a gas analyser will monitor the FiO2 and a capnography monitor (Capnostream 20, ORIDION) will also be installed.</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Good health on the basis of the medical interview, physical examination and standard&#xD;
             biology parameters.&#xD;
&#xD;
          -  Right-Handed&#xD;
&#xD;
          -  Non-smoker&#xD;
&#xD;
          -  No cardiac nor pulmonary pathologies&#xD;
&#xD;
          -  No use of chronic treatment or psychotropic drugs or substances&#xD;
&#xD;
          -  BMI inferior to 25 Kg/m2&#xD;
&#xD;
          -  French speaker and able to understand the test instructions&#xD;
&#xD;
          -  Informed consent form signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject with history or current brain disease (severe brain trauma, transient ischemic&#xD;
             attack, stroke, epilepsy, cerebral tumor…) or retinal pathologies (including familial&#xD;
             DMLA)&#xD;
&#xD;
          2. Subject with history of Acute Mountain Sickness, High Altitude Cerebral Edema or High&#xD;
             Altitude Pulmonary Edema&#xD;
&#xD;
          3. Subject with other major medical or surgical history including coronaropathy and&#xD;
             pulmonary arterial hypertension&#xD;
&#xD;
          4. Subject with current chronic disease&#xD;
&#xD;
          5. Subject with vascular or metabolic risk factor&#xD;
&#xD;
          6. Subject with history of or current mental disease or addiction (MINI)&#xD;
&#xD;
          7. Subject with significant abnormality on biology&#xD;
&#xD;
          8. Subject with significant abnormality on ECG&#xD;
&#xD;
          9. Subject with significant abnormality on MRI&#xD;
&#xD;
         10. Subject with significant abnormality of electrical activities on EEG&#xD;
&#xD;
         11. Subject with family history of young onset dementia&#xD;
&#xD;
         12. Subject with family history of cardiac or pulmonary pathologies&#xD;
&#xD;
         13. Subject with family history of chronic or severe neurological or mental disease (first&#xD;
             degree relatives)&#xD;
&#xD;
         14. Subject with claustrophobia or contraindication to MRI&#xD;
&#xD;
         15. Subject under guardianship&#xD;
&#xD;
         16. Subject not covered by Social Security&#xD;
&#xD;
         17. Subject participating in another clinical trial&#xD;
&#xD;
         18. Subject with anxiety (STAI-Trait Score T&gt; 51) or neuroticism personality (EPI Score N&#xD;
             ≥13)&#xD;
&#xD;
         19. Subject bearded or refusing to shave&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Régis Bordet</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Régis Bordet, MD,PhD</last_name>
    <email>regis.bordet@univ-lille2.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique, CHRU</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Elsa Jozefowicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre d'investigation Clinique</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christine Audebert, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 1, 2016</study_first_submitted>
  <study_first_submitted_qc>September 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>August 25, 2020</last_update_submitted>
  <last_update_submitted_qc>August 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cognitive Function</keyword>
  <keyword>Hypoxia</keyword>
  <keyword>Neurophysiological Function</keyword>
  <keyword>Effect of Alzheimer Disease symptomatic drugs</keyword>
  <keyword>Healthy Subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

